Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
432 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01520922 | Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | completed | Phase 2 | 99 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 19, 2017 | clinicaltrials |
| NCT00842712 | Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)(CERTO) | completed | Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 8 | Jan 13, 2017 |
| clinicaltrials |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients(HERMIONE) | terminated | Phase 2 / Phase 3 | 113 | Merrimack PharmaceuticalsINDUSTRY | 9 | Jan 6, 2017 | clinicaltrials |
| NCT02107378 | Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma | terminated | Phase 2 | 22 | SOTIO a.s.INDUSTRY | 3 | Nov 30, 2016 | clinicaltrials |
| NCT02465814 | Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids(ASTEROID 2) | completed | Phase 2 | 120 | BayerINDUSTRY | 16 | Nov 22, 2016 | clinicaltrials |
| NCT01087151 | A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 12 | Nov 2, 2016 | clinicaltrials |
| NCT01437566 | Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy | completed | Phase 2 | 318 | Genentech, Inc.INDUSTRY | 23 | Nov 2, 2016 | clinicaltrials |
| NCT01715896 | A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis | completed | Phase 2 | 215 | MedImmune LLCINDUSTRY | 14 | Oct 31, 2016 | clinicaltrials |
| NCT01617668 | A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer | completed | Phase 2 | 209 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 17, 2016 | clinicaltrials |
| NCT01755624 | Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET) | unknown | Phase 2 | 18 | NovoCure Ltd.INDUSTRY | 5 | Sep 21, 2016 | clinicaltrials |
| NCT00047840 | This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | completed | Phase 2 | 129 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Aug 25, 2016 | clinicaltrials |
| NCT00404703 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 37 | Hoffmann-La RocheINDUSTRY | 10 | Aug 24, 2016 | clinicaltrials |
| NCT00327535 | A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | completed | Phase 2 | 153 | Hoffmann-La RocheINDUSTRY | 15 | Aug 11, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT00682981 | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) | completed | Phase 1 / Phase 2 | 218 | Gemin XINDUSTRY | 10 | Jul 21, 2016 | clinicaltrials |
| NCT00259064 | Iressa v BSC (Best Supportive Care) in First Line NSCLC(INSTEP) | completed | Phase 2 / Phase 3 | 216 | AstraZenecaINDUSTRY | 5 | Jun 2, 2016 | clinicaltrials |
| NCT01286077 | Velcade Consolidation Bone Study | completed | Phase 2 | 106 | Janssen-Cilag International NVINDUSTRY | 8 | May 30, 2016 | clinicaltrials |
| NCT01147809 | Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | completed | Phase 2 | 130 | GlaxoSmithKlineINDUSTRY | 13 | Apr 18, 2016 | clinicaltrials |
| NCT01390545 | VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis(VELVET) | terminated | Phase 2 | 300 | TakedaINDUSTRY | 11 | Apr 13, 2016 | clinicaltrials |
| NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) | completed | Phase 2 | 202 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 15 | Apr 8, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 25 | Akinion Pharmaceuticals ABINDUSTRY | 4 | Mar 25, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT01332656 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel(OPSALIN) | completed | Phase 2 | 154 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
| NCT01478594 | A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | completed | Phase 2 | 265 | AVEO Pharmaceuticals, Inc.INDUSTRY | 12 | Jul 8, 2015 | clinicaltrials |
| NCT00796757 | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 12 | May 27, 2015 | clinicaltrials |
| NCT00529503 | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | terminated | Phase 2 | 151 | Seagen Inc.INDUSTRY | 10 | Feb 25, 2015 | clinicaltrials |
| NCT01310101 | Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 33 | Brno University HospitalOTHER | 1 | Feb 3, 2015 | clinicaltrials |
| NCT00700180 | A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 2 | 303 | Hoffmann-La RocheINDUSTRY | 16 | Sep 25, 2014 | clinicaltrials |
| NCT01151215 | Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer(MINT) | terminated | Phase 2 | 482 | AstraZenecaINDUSTRY | 18 | Jul 25, 2014 | clinicaltrials |
| NCT00265135 | A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 68 | Centocor, Inc.INDUSTRY | 4 | Jul 3, 2014 | clinicaltrials |
| NCT01208194 | Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma(IMPACT) | completed | Phase 2 | 59 | Mologen AGINDUSTRY | 6 | Jun 20, 2014 | clinicaltrials |
| NCT00328198 | Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 86 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Mar 13, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT01037478 | Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma(SAPHIRE) | completed | Phase 2 | 37 | 4SC AGINDUSTRY | 3 | Jan 16, 2014 | clinicaltrials |
| NCT00389441 | Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | completed | Phase 2 | 52 | PfizerINDUSTRY | 9 | Nov 25, 2013 | clinicaltrials |
| NCT00902915 | Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure | unknown | Phase 2 | 50 | Austrian Forum Against CancerOTHER | 2 | Nov 25, 2013 | clinicaltrials |
| NCT01168804 | Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma(BBD) | completed | Phase 2 | 79 | Austrian Forum Against CancerOTHER | 2 | Nov 25, 2013 | clinicaltrials |
| NCT00600821 | A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. | completed | Phase 2 | 118 | PfizerINDUSTRY | 6 | Nov 8, 2013 | clinicaltrials |
| NCT01038804 | A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer | completed | Phase 2 | 101 | Astellas Pharma IncINDUSTRY | 8 | Sep 18, 2013 | clinicaltrials |
| NCT00530764 | A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.(SPRAY) | completed | Phase 2 | 360 | GW Pharmaceuticals LtdINDUSTRY | 16 | Jun 20, 2013 | clinicaltrials |
| NCT00707889 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | completed | Phase 2 | 159 | AbbVie (prior sponsor, Abbott)INDUSTRY | 14 | May 15, 2013 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials